For research use only
| Cat No. | ABC-TC514S |
| Product Type | Human Lymphoma Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Burkitt’s Lymphoma |
| Product Code | BJAb; BJA-B; BJAB-1; BJA-B1; BJA-B-1 |
BJAB cells are EBV-negative Burkitt lymphoma cells commonly used in B cell biology, immune response, and lymphoid malignancy investigations.
BJAB cells is a human B-cell lymphoma cell line established in 1973 from a 5-year-old Caucasian patient with Burkitt-like lymphoma, originating from human peripheral blood lymphocytes. These suspension-growing cells exhibit typical lymphoblastic morphology and are EBV-negative, making them an excellent model for studying EBV-independent B-cell malignancies. The cells exhibit a round to polymorphic morphology, growing either singly or in large, flat clumps in suspension. BJAB cells have a complex hypotriploid to pseudodiploid karyotype with multiple chromosomal abnormalities. These cells harbor TP53 mutations and CDKN2A deletions, contributing to their tumorigenic potential. BJAB cells do not produce immunoglobulin and are negative for EBV nuclear antigen (EBNA), distinguishing them from other Burkitt lymphoma lines.
| Product Code | BJAb; BJA-B; BJAB-1; BJA-B1; BJA-B-1 |
| Species | Human |
| Cat.No | ABC-TC514S |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Disease | Burkitt’s Lymphoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lymphoma Cell Lines |
BJAB cells are extensively utilized in lymphoma research for testing novel chemotherapeutic agents, studying MYC-driven oncogenesis, and exploring apoptosis regulation. Their EBV-negative status makes them ideal for comparative studies with EBV-positive lymphoma models. BJAB also serves as an in vitro system to dissect B-cell receptor signaling and immune evasion mechanisms in aggressive B-cell malignancies.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
